CRISPR Screens Identify Vital lncRNAs
CMN Briefs
Nov. 12, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Avectas
Main focus: Next-generation delivery technology for gene editing
Company stage: Pre-clinical
Diseases: Cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Dublin, Ireland
Website: https://avectas.com/
Partners: ONK Therapeutics
Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.
